-1% Off

Mounjaro (Tirzepatide)

$1,227.00

Tirzepatide, the active compound in Mounjaro, acts as both a glucagon-like peptide-1 receptor agonist (GLP-1) and a glucose-dependent insulinotropic polypeptide receptor (GIP) agonist.

Compare
Category:

Description

Tirzepatide, the active compound in Mounjaro, acts as both a glucagon-like peptide-1 receptor agonist (GLP-1) and a glucose-dependent insulinotropic polypeptide receptor (GIP) agonist. Mounjaro, created by Eli Lilly and Company, is a clear to slightly yellow, preservative-free solution designed for subcutaneous injection. It’s available in pre-filled pens with solutions ranging from 2.5 mg to 15 mg for adults with type 2 diabetes mellitus to help manage blood sugar levels alongside diet and exercise.

Additional information

Usage

Usage
-Before using, ensure the pen isn't expired or damaged. Dispose of the Mounjaro pen if it contains particles or discolored solution. The medication can be consumed with or without food. Rotate injection sites in the stomach, thighs, and upper arm on the same day weekly to prevent skin irritation. Press and wait 10 seconds before removing the pen from the injection site or verifying the gray plunger's visibility to confirm administration completion.

Side effects

Side effects
Serious Adverse Effects If you encounter any of the following, contact your healthcare provider urgently:
• Severe allergic reaction: hives, difficulty breathing, swelling of lips, tongue, throat, or face
• Dangerously low blood sugar: excessive hunger, rapid heartbeat, shakiness, anxiety, sweating, tingling, dizziness, weakness, drowsiness, confusion
• Kidney impairment: nausea, vomiting, difficulty urinating, muscle cramps, confusion, ankle or foot swelling, breathlessness The subsequent side effects may improve as your body adjusts to the medication. Notify your healthcare provider immediately if these symptoms persist or worsen: Common Adverse Effects
• Nausea (12-18%)
• Diarrhea (12-17%)
• Reduced appetite (5-11%)
• Vomiting (5-9%)
• Stomach discomfort (5-8%)
• Constipation (6-7%)
• Abdominal pain (5-6%) Other Possible Effects
• Elevated heart rate
• Reaction at the injection site

Storage

Storage
-Patients can safely store Mounjaro pens in the refrigerator at temperatures between 36-46°F (2-8°C) until their expiration date. Pens can also be kept at room temperature (up to 86°F or 30°C) for up to 21 days. Avoid freezing or exposing the pen to light.

Warnings, Precautions, and Contraindications

Warnings, Precautions, and Contraindications
-Mounjaro is not suitable for patients with a family history of Medullary Thyroid Cancer (MTC) and Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Anaphylaxis and angioedema have been reported in patients using GLP-1 receptor agonists. Female patients on contraceptives should consider non-oral options due to Mounjaro's potential impact on gastric emptying time. The drug's safety has not been established for individuals under 18 years old.

Adverse Effect

Adverse Effect
-Increased risk of severe hypoglycemia can occur when combining Mounjaro with Insulin or insulin secretagogues. Patients using Mounjaro or other GLP-1 receptor agonists should monitor for acute renal injury, worsening chronic renal failure possibly requiring hemodialysis, temporary exacerbation of diabetic retinopathy, acute gallbladder conditions like cholelithiasis or cholecystitis, and pancreatitis.

Reviews

There are no reviews yet.

Be the first to review “Mounjaro (Tirzepatide)”

Your email address will not be published. Required fields are marked *